These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23291680)

  • 1. Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy.
    Matsuo K; Nambu T; Matsuda Y; Kanai Y; Yonemitsu S; Muro S; Oki S
    Intern Med; 2013; 52(1):89-95. PubMed ID: 23291680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.
    Jiang LL; Wang SQ; Ding B; Zhu J; Jing T; Ye L; Lee KO; Wu JD; Ma JH
    J Endocrinol Invest; 2018 May; 41(5):539-547. PubMed ID: 29032494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
    Xu S; Liu X; Ming J; Ji Q
    Trials; 2016 Mar; 17():160. PubMed ID: 27009108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.
    Davis SN; Johns D; Maggs D; Xu H; Northrup JH; Brodows RG
    Diabetes Care; 2007 Nov; 30(11):2767-72. PubMed ID: 17595353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
    Thong KY; Jose B; Blann AD; Cull ML; Mills AP; Sathyapalan T; Walton C; Ryder REJ
    Diabetes Res Clin Pract; 2011 Aug; 93(2):e87-e91. PubMed ID: 21636161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Exenatide--an alternative to insulin in the treatment of type 2 diabetes?].
    Kjeldsen R; Sandbaek A
    Ugeskr Laeger; 2008 Sep; 170(39):3039-43. PubMed ID: 18822227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
    Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study).
    Xu W; Bi Y; Sun Z; Li J; Guo L; Yang T; Wu G; Shi L; Feng Z; Qiu L; Li Q; Guo X; Luo Z; Lu J; Shan Z; Yang W; Ji Q; Yan L; Li H; Yu X; Li S; Zhou Z; Lv X; Liang Z; Lin S; Zeng L; Yan J; Ji L; Weng J
    J Intern Med; 2015 Jan; 277(1):137-50. PubMed ID: 25039675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
    Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
    Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
    Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide.
    Barnett AH
    Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
    Hoogwerf BJ
    Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
    Traina AN; Lull ME; Hui AC; Zahorian TM; Lyons-Patterson J
    Can J Diabetes; 2014 Aug; 38(4):269-72. PubMed ID: 24797495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide: its position in the treatment of type 2 diabetes.
    Guerci B; Martin CS
    Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.